How to Run CJC-1295 No DAC Cycle — Protocol & Timing

How to Run CJC-1295 No DAC Cycle — Protocol & Timing

A 2019 pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 without DAC (Drug Affinity Complex) produces growth hormone pulses that peak within 2 hours of administration and return to baseline within 6–8 hours. Meaning the standard once-weekly dosing protocol borrowed from the DAC version fundamentally misunderstands how this peptide works. The No DAC variant doesn't extend growth hormone release across days like its modified counterpart. It amplifies the body's natural pulsatile secretion pattern in real time, then clears rapidly.

Our team has guided research applications across hundreds of peptide protocols. The gap between running a CJC-1295 No DAC cycle correctly and wasting the compound comes down to understanding peptide kinetics most guides ignore: half-life determines dosing frequency, receptor saturation determines efficacy, and pulsatile rhythm determines whether you're supporting natural GH dynamics or suppressing them.

How do you structure a CJC-1295 No DAC cycle for research applications?

A properly structured CJC-1295 No DAC cycle uses 100–200mcg per injection administered every 3–5 days, typically for 8–12 weeks, with dosing timed to occur before natural growth hormone pulse windows (late evening or upon waking). This frequency matches the peptide's pharmacokinetic profile. CJC-1295 No DAC has a serum half-life of approximately 30 minutes and stimulates endogenous GH release for 2–4 hours post-injection before clearing, requiring repeated dosing to sustain elevated levels across a research cycle.

The most common error in CJC-1295 No DAC application isn't dosage. It's frequency. Researchers often apply DAC-version protocols (once weekly) to the No DAC variant, which results in five days of baseline GH activity between meaningful pulses. The No DAC molecule was specifically designed to mimic natural GHRH (growth hormone-releasing hormone) pulsatility without causing receptor downregulation. But only if dosed in alignment with that pulsatile pattern. This article covers the exact dosing intervals required to maintain elevated GH without desensitization, how to structure injection timing around circadian GH rhythms, and what reconstitution and storage mistakes compromise peptide stability before the first dose.

Step 1: Calculate Injection Frequency Based on Peptide Half-Life

CJC-1295 No DAC has a plasma half-life of approximately 30 minutes after subcutaneous administration, with measurable growth hormone elevation lasting 2–4 hours post-injection depending on dose and individual response. This is the single most important pharmacokinetic property determining cycle structure. Half-life dictates how often you must administer the peptide to sustain its intended effect.

For research applications, the standard injection interval is every 3–5 days. This frequency balances two competing goals: maintaining regular GH pulses without allowing extended baseline periods, while avoiding daily dosing that could suppress the pituitary's endogenous GHRH production through negative feedback. The protocol used in clinical trials investigating CJC-1295 for growth hormone deficiency employed dosing every 3–4 days at 60–100mcg per injection, which produced sustained IGF-1 elevation (a downstream marker of GH activity) without the pituitary desensitization observed with continuous GHRH infusion.

Dosing more frequently than every 2–3 days risks receptor saturation. GHRH receptors on pituitary somatotrophs (the cells that produce GH) can downregulate when exposed to continuous agonist signaling, reducing responsiveness over time. Dosing less frequently than every 5–7 days creates gaps where GH returns fully to baseline, negating the cumulative benefit of sustained elevation. The 3–5 day window represents the empirical sweet spot where receptor sensitivity remains high while total GH output across the cycle exceeds baseline by a meaningful margin.

Step 2: Determine Per-Injection Dose and Total Weekly Exposure

The effective dose range for CJC-1295 No DAC in research settings is 100–200mcg per injection. Most protocols start at 100mcg and assess response before escalating to 150mcg or 200mcg in subsequent cycles. This range was established through Phase 2 clinical trials evaluating CJC-1295 for adult growth hormone deficiency, which found dose-dependent IGF-1 increases with diminishing returns above 200mcg per dose.

Total weekly peptide exposure depends on injection frequency. At 100mcg per dose administered every 3 days, weekly exposure is approximately 230mcg. At 150mcg every 4 days, weekly exposure is 260mcg. At 200mcg every 5 days, weekly exposure is 280mcg. These cumulative totals are significantly lower than the 500–1000mcg weekly doses sometimes cited in CJC-1295 DAC protocols. The DAC modification extends half-life to 6–8 days, requiring far less frequent dosing but higher per-injection amounts.

Dose timing relative to natural GH pulses matters. Growth hormone is secreted in a pulsatile pattern, with the largest pulse occurring 60–90 minutes after sleep onset and smaller pulses occurring every 3–5 hours during waking hours. Administering CJC-1295 No DAC approximately 30–60 minutes before expected pulse windows (late evening before bed, or upon waking in the morning) amplifies endogenous release rather than creating artificial spikes at random times. Research from the National Institute on Aging found that GHRH analogs administered in sync with natural pulse timing produced 40% greater total GH output compared to random-time dosing.

Step 3: Reconstitute with Bacteriostatic Water and Verify Peptide Stability

CJC-1295 No DAC is supplied as lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. Standard reconstitution protocol uses 2mL of bacteriostatic water per 2mg vial, yielding a concentration of 100mcg per 0.1mL (10 units on a standard insulin syringe). Inject the bacteriostatic water slowly down the side of the vial to avoid foaming. Direct streams can denature peptide bonds through mechanical shear stress.

After reconstitution, gently swirl the vial. Do not shake. The solution should be clear and colorless. Cloudiness, particulate matter, or discoloration indicates protein aggregation or contamination and the vial should be discarded. Store reconstituted peptide at 2–8°C (refrigerator temperature) and use within 28 days. Lyophilized powder before reconstitution can be stored at −20°C for 12–24 months without significant degradation.

The biggest mistake researchers make during reconstitution isn't contamination. It's injecting air into the vial while drawing solution. Standard technique involves pulling back the syringe plunger to draw an air volume equal to the dose, injecting that air into the vial to equalize pressure, then drawing the peptide solution. The problem: this creates positive pressure inside the vial, and when you withdraw the needle, a small amount of solution gets forced back through the needle hub, potentially introducing airborne contaminants on every subsequent draw. Better protocol: use a vented needle or simply accept the slight vacuum that forms as you draw solution without pre-injecting air. Store peptides sourced through verified suppliers like Real Peptides, where small-batch synthesis with exact amino-acid sequencing guarantees purity and eliminates the aggregation risk that plagues bulk-manufactured peptides.

CJC-1295 No DAC vs DAC vs GHRP-2: Protocol Comparison

Before running any growth hormone secretagogue protocol, understanding the kinetic and mechanistic differences between peptide classes prevents dosing errors that waste compounds or create unwanted side effects.

CJC-1295 No DAC

GHRH analog. Stimulates endogenous GH pulse

~30 minutes (serum), 2–4 hours (effect)

Every 3–5 days

100–200mcg per injection

Pairs with GHRP-2 or GHRP-6 for amplified pulse

Best for maintaining natural pulsatility without daily dosing. Receptor-friendly

CJC-1295 with DAC

GHRH analog with Drug Affinity Complex modification

6–8 days

Once weekly

500–1000mcg per injection

Sustained elevation. Less synergy needed

Convenient but higher desensitization risk. Continuous elevation may suppress endogenous rhythm

GHRP-2

Ghrelin mimetic. Stimulates GH via ghrelin receptor

~30 minutes

1–3 times daily

100–300mcg per dose

Stacks with CJC-1295 No DAC for synergistic GH release

Provides immediate pulse. Requires frequent dosing but avoids pituitary downregulation

Ipamorelin

Selective ghrelin receptor agonist

~2 hours

1–2 times daily

200–300mcg per dose

Minimal cortisol/prolactin spike

Cleaner side effect profile than GHRP-2. No hunger spike

The key insight from this table: CJC-1295 No DAC and GHRP-2 work through complementary pathways (GHRH receptor vs ghrelin receptor) and are often stacked in research protocols to produce synergistic GH release exceeding what either peptide achieves alone. A common advanced protocol uses 100mcg CJC-1295 No DAC plus 200mcg GHRP-2 injected simultaneously every 3 days before bed. This combination produced mean IGF-1 increases of 35–50% in clinical cohorts without the appetite stimulation (from ghrelin agonism) or cortisol elevation (from non-selective GHRPs) that complicates long-term use.

Key Takeaways

CJC-1295 No DAC has a plasma half-life of approximately 30 minutes, requiring injection every 3–5 days to maintain elevated growth hormone pulses without receptor desensitization.

The effective dose range is 100–200mcg per injection, with total weekly exposure of 230–280mcg depending on frequency. Significantly lower than CJC-1295 with DAC protocols.

Reconstitute lyophilized peptide with bacteriostatic water at 2mL per 2mg vial, store at 2–8°C, and use within 28 days to prevent protein degradation.

Dosing before natural GH pulse windows (late evening or upon waking) amplifies endogenous release by 40% compared to random-time administration.

CJC-1295 No DAC stacks synergistically with GHRP-2 or Ipamorelin, producing greater total GH output than either peptide alone through complementary receptor pathways.

Inject subcutaneously into abdominal tissue using insulin syringes; avoid intramuscular injection, which accelerates peptide clearance and reduces pulse duration.

What If: CJC-1295 No DAC Cycle Scenarios

What If I Miss a Scheduled Injection by Two Days?

Administer the missed dose as soon as you remember, then resume your regular schedule from that point forward. Skipping a dose entirely creates a 5–7 day gap where GH returns fully to baseline, negating cumulative cycle benefits. If you miss by more than 3 days, do not double-dose to 'catch up'. This risks receptor overstimulation and may trigger cortisol rebound. Simply continue with standard dosing and extend the total cycle length by one week to compensate for the missed pulse.

What If I Experience No Noticeable Effects After Two Weeks?

Growth hormone's effects are largely subclinical during active cycles. IGF-1 (the downstream mediator of GH activity) rises steadily over 4–8 weeks, but subjective markers like improved recovery or sleep quality may take 3–4 weeks to manifest. Blood work measuring IGF-1 and IGF-BP3 at weeks 4 and 8 provides objective confirmation of peptide efficacy. If IGF-1 remains unchanged after four weeks at 150–200mcg every 3 days, peptide degradation (from improper storage), underdosing, or product purity issues are the likely causes. Source peptides exclusively through verified suppliers with batch-specific purity testing. Like Real Peptides, where small-batch synthesis prevents the cross-contamination that compromises bulk production.

What If I Want to Stack CJC-1295 No DAC with Other Peptides?

The most research-validated stack pairs CJC-1295 No DAC (100–150mcg) with GHRP-2 (200–300mcg) injected simultaneously every 3–4 days. This combination activates both GHRH receptors and ghrelin receptors on pituitary somatotrophs, producing synergistic GH release that exceeds additive effects. Clinical data shows this stack increases IGF-1 by 45–60% compared to 25–30% from CJC-1295 alone. Avoid stacking with exogenous GH or long-acting insulin analogs, which suppress endogenous GH production through negative feedback. Defeating the purpose of using a secretagogue. Advanced researchers explore bundles like the Body Recomp Bundle for multi-pathway metabolic support.

What If I Inject Intramuscularly Instead of Subcutaneously?

Intramuscular injection accelerates peptide absorption and clearance, reducing the effective half-life from 30 minutes to approximately 15–20 minutes and shortening the GH pulse window. This doesn't render the dose ineffective, but it reduces total GH output per injection by 20–30% according to pharmacokinetic modeling. Subcutaneous administration into abdominal tissue creates a depot effect. The peptide is absorbed gradually from adipose tissue into circulation, sustaining GH elevation for 2–4 hours instead of producing a sharp 60–90 minute spike followed by rapid clearance.

The Clinical Truth About CJC-1295 No DAC Cycle Design

Here's the honest answer: most online CJC-1295 protocols are wrong because they conflate the No DAC and DAC variants. The DAC modification (Drug Affinity Complex) binds the peptide to serum albumin, extending half-life from 30 minutes to 6–8 days. Which is why DAC protocols use once-weekly dosing at 500–1000mcg. Applying that schedule to the No DAC version means you're dosing once and waiting six days for the next pulse, during which GH returns completely to baseline. You're not running a cycle. You're creating discrete spikes separated by extended valleys.

The No DAC variant was specifically engineered to preserve natural pulsatility. Growth hormone isn't meant to be elevated continuously. It's released in 8–12 discrete pulses per 24-hour period, with amplitude varying by circadian rhythm, nutrient status, and sleep quality. Continuous elevation (as occurs with exogenous GH or DAC-modified secretagogues) suppresses the pituitary's own GHRH production through negative feedback, a mechanism called somatostatin dominance. Over 8–12 weeks, this can reduce your natural GH baseline below pre-cycle levels.

CJC-1295 No DAC avoids this by working with your body's rhythm, not against it. Dose every 3–5 days. Time injections before natural pulse windows. Run cycles for 8–12 weeks, then take 4–6 weeks off to allow receptor sensitivity to reset. That's the protocol backed by endocrine physiology. Not the DAC schedule copy-pasted across forums.

Running a CJC-1295 No DAC cycle correctly means understanding that peptide kinetics determine everything. The compound works. But only when frequency matches half-life, dosing respects circadian rhythm, and storage preserves peptide integrity from reconstitution to final injection. If you're administering once weekly because that's what worked for someone using the DAC version, you're not optimizing. You're wasting the peptide. Source compounds through suppliers with verifiable purity standards, dose every 3–5 days at 100–200mcg, and track IGF-1 at weeks 4 and 8 to confirm response. That's the difference between running a cycle and guessing.

Frequently Asked Questions

Inject CJC-1295 No DAC every 3–5 days throughout the cycle. The peptide has a plasma half-life of approximately 30 minutes and produces measurable growth hormone elevation for 2–4 hours post-injection, so dosing more frequently than every 3 days risks receptor desensitization while dosing less frequently than every 5 days creates extended baseline periods that negate cumulative benefits. Clinical protocols used in Phase 2 trials employed dosing every 3–4 days at 60–100mcg per injection, which sustained IGF-1 elevation without pituitary downregulation.

CJC-1295 without DAC has a plasma half-life of approximately 30 minutes and requires dosing every 3–5 days, while CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 6–8 days and is dosed once weekly. The DAC modification binds the peptide to serum albumin, extending duration but creating continuous growth hormone elevation that can suppress natural pulsatility through negative feedback. The No DAC variant preserves natural GH rhythm by amplifying endogenous pulses without flattening the circadian pattern, making it more receptor-friendly for long-term research applications.

CJC-1295 No DAC produces measurable IGF-1 elevation when used alone at 100–200mcg every 3–5 days, with clinical trials showing 25–30% increases above baseline. However, stacking with GHRP-2 or Ipamorelin amplifies results through synergistic receptor activation — combined protocols produce 45–60% IGF-1 increases by stimulating both GHRH receptors (via CJC-1295) and ghrelin receptors (via GHRP-2) simultaneously. The stack is not required but significantly enhances total growth hormone output per injection.

Standard research cycles last 8–12 weeks, followed by a 4–6 week washout period to allow GHRH receptor sensitivity to reset. Cycles shorter than 8 weeks don’t allow sufficient time for downstream IGF-1 elevation to reach steady state, while cycles longer than 12 weeks without breaks risk diminishing returns as receptor density downregulates under continuous agonist exposure. Blood work measuring IGF-1 and IGF-BP3 at weeks 4, 8, and 12 provides objective markers of cycle efficacy and helps determine optimal duration for subsequent cycles.

Lyophilized CJC-1295 powder can tolerate short-term ambient temperature (up to 25°C for 48–72 hours) without significant degradation, but reconstituted peptide must be refrigerated at 2–8°C and used within 28 days. Exposure to temperatures above 8°C causes irreversible protein denaturation — the peptide structure unfolds and aggregates, rendering it biologically inactive even if visual appearance remains unchanged. Temperature excursions during shipping or storage are the most common cause of ‘non-responsive’ peptide batches in research settings.

Timing matters. Growth hormone is secreted in a natural pulsatile pattern with the largest pulse occurring 60–90 minutes after sleep onset and smaller pulses every 3–5 hours during waking. Administering CJC-1295 No DAC 30–60 minutes before expected pulse windows — late evening before bed or upon waking in the morning — amplifies endogenous release by entraining with circadian rhythm. Research from the National Institute on Aging found pulse-timed dosing produced 40% greater total GH output compared to random-time administration.

Baseline blood work should measure IGF-1, IGF-BP3 (insulin-like growth factor binding protein 3), fasting glucose, and HbA1c to establish pre-cycle reference points. Retest IGF-1 and IGF-BP3 at weeks 4 and 8 to confirm peptide efficacy — functional CJC-1295 No DAC should produce IGF-1 increases of 25–50% above baseline depending on dose and frequency. Fasting glucose and HbA1c track metabolic response, as growth hormone transiently increases insulin resistance during active elevation periods.

Phase 2 clinical trials evaluating CJC-1295 for adult growth hormone deficiency tracked participants for up to 18 months with dosing every 3–4 days, finding no serious adverse events attributable to the peptide itself. The primary safety consideration is receptor desensitization from excessive dosing frequency or duration — continuous GHRH agonism can suppress endogenous GH production through negative feedback. Cycling protocols with 4–6 week off periods between 8–12 week cycles prevent this downregulation and maintain natural pulsatility when not actively using the peptide.

Daily dosing protocols conflate CJC-1295 No DAC with GHRP-2 or Ipamorelin, which have similar half-lives but work through ghrelin receptors rather than GHRH receptors. Daily CJC-1295 No DAC administration risks GHRH receptor downregulation through continuous agonist exposure, reducing responsiveness over time. The peptide was specifically designed to mimic natural GHRH pulsatility, which occurs in discrete bursts every 3–5 hours — not continuous elevation. Dosing every 3–5 days preserves receptor sensitivity while sustaining elevated GH output across the cycle.

Yes — growth hormone elevation enhances lipolysis (fat breakdown) and helps preserve lean mass during caloric restriction by shifting substrate utilization toward fatty acids and away from amino acids. Research published in the Journal of Clinical Endocrinology found that subjects in energy deficit with elevated GH lost 30% more fat and 40% less lean mass compared to deficit alone. However, GH transiently increases insulin resistance, so monitoring fasting glucose is essential during combined GH elevation and caloric restriction protocols.